Pacira Pharmaceuticals, Inc. Reports Preliminary Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended of December 31, 2016
January 06, 2017 at 12:42 pm
Share
Pacira Pharmaceuticals, Inc. reported preliminary unaudited consolidated earnings results for the fourth quarter and year ended of December 31, 2016. For the quarter, the company reported total revenues of $72.9 million, compared to $69.3 million for the fourth quarter of 2015. Net product sales for the fourth quarter of 2016 were $71.4 million, compared to $67.2 million for the fourth quarter of 2015.
Total revenues for 2016 were $276.4 million, compared to $249.0 million for 2015. Net product sales for 2016 were $265.8 million, compared to $239.9 million for 2015.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
PACIRA BIOSCIENCES, INC. 
